bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.81 | $1M | -$3M |
| 2025 Q4 | -1.82 | $2M | -$2M |
| 2025 Q3 | -4.74 | $1M | -$2M |
| 2025 Q2 | -5.07 | $1M | -$3M |
| 2025 Q1 | -4.80 | $2M | -$2M |
| 2024 Q4 | -6.30 | $2M | -$2M |
| 2024 Q3 |
| -4.80 |
| $2M |
| -$2M |
| 2024 Q2 | -5.70 | $2M | -$2M |